2Bruix J, Sherman M. Asherman association for the study of liver dis- eases. Management of hepatoccllular carcinoma: an update [J]. Hcp- atology, 2011, 53(3): 1020-1022.
3Garcia M, Jemal A, Ward EM, et al. Global cancer facts figures [M]. Atlanta (GA): American Cancer Society, 2007: 254-259.
4Hsu C, Shen YC, Cheng CC, et al. Geographic difference in surviv- al outcome for advanced hepatocellular carcinoma: implications on future clinical trial design [J]. Contemp Clin Trials, 2010, 31(1): 55-61.
5Dupuy DE, Zaqoria R J, Akerley W, et al. Percutaneous radiofre- quency ablation of malignancies in the lung [J]. AJR Am roentqenol, 2000, 174(1): 57-59.
6Mizukoshi E, Nakamoto Y, Arai K, et al. Enhancement of tumor-spe- cific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma [J]. Int J Can- cer, 2010, 126(9): 2164-2174.
7Linn YC, Lau SK, Liu BH, et al. Characterization of recognition and functional heterogeneity exhibited by ytokine-induced killer cell subsets against acute myeloid leukaemia target cell [J]. Immu- nology, 2009, 126(3): 423-435.
8Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy to- wards successful cancer treatment [J]. Immanotherapy, 2010, 2(1): 37-56.
9Kobayashi M, Ikeda K, Kawamura Y, et al. Randomized controlled trial for the efficacy of hepatic arteria occlusion during radiofrc- quency ablation for small hepatocellular carcinoma-direct ablative effects and a long-term outcome [J]. Liver Int, 2007, 27(3): 353-359.
10Kroeze SG, Daenen LG, Nijkamp MW, et al. Radio frequency ablation and immunotherapy [J]. Front Biosci, 2008, 13(2): 369-381.
